PHA665752 is primarily used in research settings as a selective inhibitor of the c-Met (mesenchymal-epithelial transition factor) receptor tyrosine kinase. It is a valuable tool in studying the role of c-Met signaling pathways in cancer biology, particularly in understanding tumor growth, metastasis, and angiogenesis. Researchers utilize PHA665752 to investigate the potential of c-Met inhibition as a therapeutic strategy in cancers where this pathway is dysregulated, such as in certain types of lung, liver, and gastric cancers. Its application helps in developing targeted therapies and assessing the efficacy of c-Met inhibitors in preclinical models.